CompletedNCT01569659
Higher or Standard Lurasidone Doses for Treatment-Resistant Schizophrenia
About this title
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
Read the official source — NCT01569659Medication studyAges 18–60United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Chicago and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 101
- Sponsor
- Northwestern University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01569659
- Official title
Show the full official title
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
Get this study by email
Recruitment & locations
CompletedChicago
Questions about this study
Who is behind this study?
The study sponsor is Northwestern University, a university.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia